作者:Hualong He、Xi Hu、Fei Teng、Zhihao Liu、Qiangsheng Zhang、Zhanzhan Feng、Qiang Feng、Luoting Yu
DOI:10.1016/j.bmcl.2020.126957
日期:2020.3
Enhancer of zeste homolog 2 (EZH2) serves as the catalytic subunit of the polycomb repression complex 2 (PRC2), which is implicated in cancer progression metastasis and poor prognosis. Based on our EZH2 inhibitor SKLB1049 with low nanomolar activity, we extended the "tail" region to get a series of (E)-1,2-diphenylethene derivatives as novel EZH2 inhibitors. SAR exploration and preliminary assessment
zeste同源物2(EZH2)的增强子是多梳抑制复合物2(PRC2)的催化亚基,与癌症进展转移和不良预后有关。基于具有低纳摩尔活性的EZH2抑制剂SKLB1049,我们扩展了“尾巴”区域,获得了一系列作为新型EZH2抑制剂的(E)-1,2-二苯乙烯衍生物。SAR探索和初步评估导致发现了有效的新型EZH2抑制剂9b(EZH2WT IC50 = 22.0 nM)。化合物9b抑制WSU-DLCL2和SU-DHL-4细胞系的增殖(IC50分别为1.61 µM和2.34 µM)。生物学评估表明,9b是野生型EZH2的有效抑制剂,并以浓度依赖的方式大大降低了H3K27me3的总体水平。进一步的研究表明9b可以显着诱导SU-DHL-4细胞凋亡。这些发现表明9b将是用于进一步优化和评估的有吸引力的先导化合物。